Abstract
Congenital dysfibrinogenemia is a rare autosomal recessive bleeding disorder, which is characterized by the absence of functional fibrinogen. Patients may have bleeding and paradoxical arterial and venous thrombotic problems from early childhood. The optimal antithrombotic therapy in these patients hasn’t been determined yet. In this report we present a dysfibrogenemic patient, who has suffered recurrent arterial thrombosis under aspirin treatment. Intravenous fibrinogen concentrates (fc) along with reduced doses of rivaroxaban (10 mg daily), cilostazol (50 mg bid) and aspirin (100 mg daily) were given as antithrombotic treatment. The pain and the cyanosis clinically recovered within 6 weeks. This is, to our knowledge, the first time in which a new oral anticoagulant, rivaroxaban and cilostazol combination was used in a dysfibrinogenemic patient with thrombotic episodes. We determined the type, the dosage and the duration of antithrombotic treatment according to the clinical progress of the symptoms. Rivaroxaban, cilostazol and fibrinogen concentrate replacement; combination may represent a useful alternative for the antithrombotic treatment in dysfibrinogenemic patients.
References
Ulutin ON, Ulutin SB (1970) Fibrinogen Istanbul. Hematoloji (Istanbul) 1:153–166
De Bosh NB, Mosesson MW, Ruiz-Saez A, Echenaguacia M, Rodriguez-Lemoin A (2002) Inhibition of thrombin generation in plasma by fibrin formation (Antitrombin I). Thromb Haemost 88:253–258
Teresa SM, Marta M, Emiliano DB, Mariangela F, Raffaele P, Ezio Z (2015) Rare bleeding disorders. Thrombosis of abdominal aorta in congenital afibrinogenemia: case report and review of literature. Haemophilia 21:88–94
Girolami A, Ruzzon E, Tezza F, Scandellari R, Vettore S, Girolami B (2006) Arterial and venous thrombosis in rare congenital bleeding disorders: a critical review. Haemophilia 12:345–351
Grandone E, Tiscia G, Cappucci F, Favuzzi G, Santacroce R, Pisanelli D et al (2012) Clinical histories and molecular characterization of two afibrinogenemic patients: insights into clinical management. Haemophilia 18(1):e16–e18
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
As authors of this manuscript, we do not have potential conflict of interest.
Human and Animal Rights Statement
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.
Informed Consent
Informed consent was obtained from the patient.
Rights and permissions
About this article
Cite this article
Ozker, E., Atalay, F., Gulmez, O. et al. Treating a Patient of Dysfibrinogenemia with Acute Thromboembolism by Rivaroxaban and Cilostazol. Indian J Hematol Blood Transfus 33, 431–433 (2017). https://doi.org/10.1007/s12288-016-0751-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12288-016-0751-2